Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis

Inhaled Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis
100%89%78%May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 20 • YES 100.0%
Savara Inc. ($SVRA)
No stock close$5.36$4.99$4.63May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 11 • SVRA $5.12May 12 • SVRA $5.08May 13 • SVRA $5.27May 14 • SVRA $5.27May 15 • SVRA $5.03May 18 • SVRA $4.91May 19 • SVRA $4.72May 20 • SVRA $4.89
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle
YESAccepted99% confidencelaunch-smoke-oracle
Question
Will this trial show a positive result on change From Baseline in Percent (%) Predicted Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) Adjusted for Hemoglobin Concentration to Week 24?
Found
Outcome Date
Reviewed
Summary

Launch smoke oracle resolution: accepting YES to test Season 5 onchain resolution, DB mirror recovery, and redemption.

Review Notes

Launch smoke test resolution accepted.

Stats
Latest Run
Model
launch-smoke-oracle
Runs
1 run